effects of refractory status to lenalidomide of xvd versus vd in pts with previously treated mm
Published 3 years ago • 171 plays • Length 6:30Download video MP4
Download video MP3
Similar videos
-
3:26
effect of lenalidomide-refractory status on safety and efficacy of xvd versus vd in myeloma
-
3:30
what does it mean to be refractory to revlimid®? what other treatment options are available?
-
4:01
pomalidomide low-dose dex dara in relapsed and/or refractory multiple myeloma
-
1:57
treatment options for patients with multiple myeloma refractory to lenalidomide
-
5:28
daratumumab with ixazomib and dex in pts with one prior lenalidomide-based regimen: the daria study
-
3:10
what impact do revlimid® (lenalidomide) and pomalyst® (pomalidomide) have on the bone marrow?
-
5:23
4-year follow-up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone
-
2:24
biomarkers to predict outcomes in patients with myeloma treated with lenalidomide and dexamethasone
-
38:16
managing multiple myeloma symptoms and treatment side effects - rcw pacific nw
-
3:14
what are the frontline myeloma treatment options?
-
2:30
carfilzomib thalidomide and dexamethasone is safe and effective in the treatment of rrmm
-
3:49
gmmg-hd4 and mm5: bortezomib vs. lenalidomide for myeloma maintenance
-
28:53
myeloma nurse experts: how to manage myeloma symptoms and side effects
-
1:07
lenalidomide maintenance – an active approach to treating mm?
-
42:37
rcw kansas - how to manage myeloma symptoms and side effects
-
2:29:01
new strategies for multiple myeloma care: next steps for the future
-
4:22
future maintenance therapy approaches for multiple myeloma
-
6:33
the phase 3 tourmaline-mm2 trial
-
29:08
newly diagnosed multiple myeloma, response, bone health, renal health, mrd, survivorship care